Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel
NASDAQ:IMVT

Immunovant Q1 2026 Earnings Results & Report

Immunovant logo
$37.04 +1.33 (+3.72%)
Closing price 04:00 PM Eastern
Extended Trading
$37.03 -0.01 (-0.03%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant beat analyst earnings expectations in its Q1 2026 results, released August 11, 2025. The company reported EPS of -$0.60 versus the -$0.69 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Immunovant EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$0.60
EPS Beat Rate
4 of last 8 quarters

Immunovant Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunovant's Q1 2026 Press ReleasePress Release
(8-K)
Immunovant's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Immunovant Q1 2026 Earnings FAQ

Immunovant (NASDAQ:IMVT) reported earnings of -$0.60 per share for Q1 2026, beating the consensus estimate of -$0.69. The report was announced on Monday, August 11, 2025.

Immunovant Earnings Headlines

Immunovant (IMVT) Q2 2027 Earnings Call Transcript
November 9 at 11:30 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunovant-imvt-q2-2027-earnings-020328896.html
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
November 9 at 6:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4965305-immunovant-inc-imvt-q2-2027-earnings-call-transcript
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
November 11 at 1:00 AM  |  Porter & Company (Ad)
Immunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
November 9 at 1:28 PM  |  marketscreener.comM
S&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences Lead
November 9 at 8:27 AM  |  barrons.comhttps://www.barrons.com/articles/s-p-500-futures-up-in-premarket-trading-immunovant-roivant-sciences-lead-7a4d80dc
Immunovant IMVT-1402 RA Win Shapes a $6.3 Billion Bet on the FDA
November 9 at 8:27 AM  |  247wallst.comhttps://247wallst.com/cards/immunovant-q2-2027-earnings-imvt-01m703n5f59bmgkhs2th7749ff
See More Immunovant Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email.

About Immunovant

Immunovant (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies.

The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders. Its medicines are investigational and are not approved for commercial use.

Immunovant was launched by Roivant Sciences in 2018 and remains part of the Roivant group. The company is led by President and Chief Executive Officer Peter Salzmann.

View Immunovant Profile
Earnings Tools